Dr. Suresh Veeramani
My Social Links

Dr. Suresh Veeramani

Research Scientist
University of Iowa, USA


Highest Degree
Ph.D. in Veterinary Immunology from Indian Veterinary Research Institute, India

Share this Profile

Biography

Dr. Suresh Veeramani is currently working as Assistant Research Scientist at the University of Iowa, United States. He obtained his PhD in Immunology from Indian Veterinary Research Institute UP, India. Dr. Suresh Veeramani is trained as Cancer Researcher with translational focus. He has been doing research in the areas of Immunology and Cancer biology for the past 16 years. His research focus includes, elucidating the intrinsic and extrinsic pathways involved in carcinogenesis and progression, understanding the role of tumor microenvironment in anti-tumor immunity, and development of innovative translational approaches to manipulate anti-tumor immune cells. He currently works as an Assistant Research Scientist at the University of Iowa. His long term goal is elucidating the mechanisms of immune regulation during cancer progression and identifying ways to enhance immunity against cancer. His work focuses on developing novel RNA aptamer-based therapeutic reagents to reverse immune-suppression seen in infections and cancer. He also studies the role of innate immune mechanisms in induction of T regulatory cells in the tumor microenvironment. He has published 18 academic writings in journals as author/co-author.

Area of Interest:

Biomedical Sciences
100%
Immunology
62%
Oncology
90%
Tumor Immunology
75%
Oxidative Stress
55%

Research Publications in Numbers

Books
0
Chapters
1
Articles
29
Abstracts
4

Selected Publications

  1. Veeramani, S., Y.W. Chou, F.C. Lin, S. Muniyan and F.F. Lin et al., 2012. Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. Free Radic Biol. Med., 53: 95-108.
    PubMed  |  Direct Link  |  
  2. Veeramani, S., S.Y. Wang, C. Dahle, S. Blackwell and L. Jacobus et al., 2011. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood, 118: 3347-3349.
    PubMed  |  Direct Link  |  
  3. Rajendran, M., P. Thomes, L. Zhang, S. Veeramani and M.F. Lin, 2010. p66Shc: A longevity redox protein in human prostate cancer progression and metastasis: p66Shc in cancer progression and metastasis. Cancer Metastasis Rev., 29: 207-222.
    CrossRef  |  PubMed  |  Direct Link  |  
  4. Chuang, T.D., S.J. Chen, F.F. Lin, S. Veeramani and S. Kumar et al., 2010. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem., 285: 23598-23606.
    CrossRef  |  
  5. Wang, S.Y., S. Veeramani, E. Racila, J. Cagley and D.C. Fritzinger et al., 2009. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood, 114: 5322-5330.
    PubMed  |  
  6. Veeramani, S., M.S. Lee and and M.F. Lin, 2009. Revisiting histidine-dependent acid phosphatases: A distinct group of tyrosine phosphatases. Trends Biochem. Sci., 34: 273-278.
    PubMed  |  
  7. Veeramani, S., T.C. Yuan, F.F. Lin and M.F. Lin, 2008. Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. Oncogene, 27: 5057-5068.
    PubMed  |  
  8. Alam, S.M., M. Rajendran, S. Ouyang, S. Veeramani, L. Zhang and M.F. Lin, 2008. A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocr. Relat. Cancer, 16: 1-16.
    CrossRef  |  
  9. Yuan, T.C., S. Veeramani and M.F. Lin, 2007. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer, 14: 531-547.
    PubMed  |  
  10. Yuan, T.C., F.F. Lin, S. Veeramani, S.J. Chen, H.S. Earp 3rd and M.F. Lin, 2007. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. Oncogene, 26: 7552-7559.
    PubMed  |  
  11. Yuan, T.C., S. Veeramani, F.F. Lin, D. Kondrikou and S. Zelivianski et al., 2006. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer, 13: 151-167.
    CrossRef  |  PubMed  |  Direct Link  |  
  12. Veeramani, S., T.C. Yuan, S.J. Chen, F.F. Lin and J.E. Petersen et al., 2005. Cellular prostatic acid phosphatase: A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Cancer, 12: 805-822.
    CrossRef  |  PubMed  |  Direct Link  |  
  13. Veeramani, S., T. Igawa, T.C. Yuan, F.F. Lin and M.S. Lee et al., 2005. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene, 24: 7203-7212.
    Direct Link  |